Compare Simon Property Group Inc (SPG) vs 10X Genomics Inc (TXG) Price & Performance

SPG trades at $199.96, up 1.2% over the past day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with revenue of $6.36B and net income of $4.63B, though Q2 2026 earnings missed expectations. Analyst consensus is a $222.90 price target with 42% buy ratings. Recent news highlights strong leasing demand and a new media network launch, while rising bond yields pose a sector headwind.

SPG offers value with a P/E of 14.09 and robust profitability margins, but faces risks from high leverage with $24.21B in long-term debt and sensitivity to interest rates. The stock's current price below the consensus target suggests potential upside if operational strength continues, though investors should weigh debt maturities and economic cyclicality.

10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.

The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.